Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV	Actinomycetales infectious disease, Bacterial Infections and Mycoses, Blood-Borne Infections, Genital Diseases, HIV Seropositivity, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, bacterial infectious disease, disease arising from reactivation of latent virus, gram-positive bacterial infections, immune system disorder, inborn error of immunity, infectious disease, latent tuberculosis infection, lentivirus infection, mycobacterial infectious disease, sexually transmitted disease, tuberculosis, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease	Active, not recruiting	Phase 1 / Phase 2	2025-12-12		NCT05122026

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Johns Hopkins University	579
The Aurum Institute NPC	5
University of Washington	397
Weill Medical College of Cornell University	276

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
FAMily Centre for Research with Ubuntu (FAMCRU)	Cape Town	South Africa	1
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital	Klerksdorp	South Africa	2
The Aurum Institute: Tembisa Clinical Research Centre	Tembisa	South Africa	2